ImportRefusal LogoImportRefusal

Sciegen Pharmaceuticals Inc

⚠️ Moderate Risk

FEI: 3008298016 • Hauppauge, NY • UNITED STATES

FEI

FEI Number

3008298016

📍

Location

Hauppauge, NY

🇺🇸
🏢

Address

89 Arkay Dr, , Hauppauge, NY, United States

Moderate Risk

FDA Import Risk Assessment

42.7
LowModerateHighCritical

This firm has a moderate history of FDA import refusals. Some attention may be warranted.

Statistics

3
Total Refusals
4
Unique Violations
3/22/2023
Latest Refusal
11/26/2021
Earliest Refusal

Score Breakdown

Violation Severity
70.0×40%
Refusal Volume
22.3×30%
Recency
28.8×20%
Frequency
22.8×10%
How is this score calculated?

Proprietary Algorithm

  • 40% Violation Severity — AI-assessed (1-10)
  • 30% Refusal Volume — Logarithmic scale
  • 20% Recency — Decays over 5 years
  • 10% Frequency — Refusals per year

© ImportRefusal.com Original Analysis

Violation Summary

1181×

NOT LISTED

It appears the drug or device is not included in a list required by Section 510(j), or a notice or other information respecting it was not provided as required by section 510(j) or 510(k).

1791×

AGR RX

The article appears to be a prescription drug manufactured in the U.S. and offered for import by other than the manufacturer and reimportation does not appear to have been authorized by the Secretary for use in a medical emergency.

721×

NEW VET DR

The article is subject to refusal of admission pursuant to Section 801(a)(3) of the Federal Food, Drug, and Cosmetic Act in that it appears to be a new animal drug that is unsafe within the meaning of Section 512(a) of the Federal Food, Drug, and Cosmetic Act as it is not the subject of an approved new animal drug application, conditionally approved new animal drug application, or index listing, and no investigational new animal drug exemption applies.

751×

UNAPPROVED

The article is subject to refusal of admission pursuant to Section 801(a)(3) in that it appears to be a new drug within the meaning of Section 201(p) without an approved New Drug Application (NDA).

Refusal History

DateProductViolationsDivision
3/22/2023
61PDA55METFORMIN HCL (ANTI-DIABETIC)
179AGR RX
Division of West Coast Imports (DWCI)
9/6/2022
61PCA55METFORMIN HCL (ANTI-DIABETIC)
118NOT LISTED
75UNAPPROVED
Division of Southeast Imports (DSEI)
11/26/2021
61NQA69GABAPENTIN (ANTI-DEPRESSANT)
72NEW VET DR
Division of Southeast Imports (DSEI)

Frequently Asked Questions

What is Sciegen Pharmaceuticals Inc's FDA import refusal history?

Sciegen Pharmaceuticals Inc (FEI: 3008298016) has 3 FDA import refusal record(s) in our database, spanning from 11/26/2021 to 3/22/2023.

What is an FEI number?

FEI stands for Firm Establishment Identifier. It's a unique number assigned by the FDA to identify establishments that manufacture, process, pack, or hold food, drugs, medical devices, or other FDA-regulated products. Sciegen Pharmaceuticals Inc's FEI number is 3008298016.

What types of violations has Sciegen Pharmaceuticals Inc received?

Sciegen Pharmaceuticals Inc has been cited for 4 different violation type(s). Common FDA violations include adulteration (unsafe or unsanitary products), misbranding (incorrect or misleading labels), and regulatory non-compliance.

Where does this information about Sciegen Pharmaceuticals Inc come from?

All FDA import refusal data for Sciegen Pharmaceuticals Inc is sourced from the official FDA Data Dashboard (datadashboard.fda.gov), a public government database maintained by the U.S. Food and Drug Administration.

Data sourced from the FDA Data Dashboard, a public database maintained by the U.S. Food and Drug Administration.